|Trade names||Cidomycin, Septopal, Genticyn, Garamycin, others|
|IV, eye drop, IM, topical|
|ATC code||D06AX07 (WHO) J01GB03 (WHO) S01AA11 (WHO) S02AA14 (WHO) S03AA06 (WHO) QA07AA91 (WHO) QG01AA91 (WHO) QG51AA04 (WHO) QJ51GB03 (WHO)|
|Bioavailability||limited bioavailability by mouth|
|Biological half-life||2 h|
|Chemical and physical data|
|Molar mass||477.596 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Gentamicin, sold under brand names Garamycin among others, is an antibiotic used to treat several types of bacterial infections. This may include bone infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, and sepsis among others. It is not effective for gonorrhea or chlamydia infections. It can be given intravenously, by injection into a muscle, or topically. Topical formulations may be used in burns or for infections of the outside of the eye. In the developed world it is often only used for two days until bacterial cultures determine what antibiotics the infection is sensitive to. The dose required should be monitored by blood testing.
Gentamicin can cause inner ear problems and kidney problems. The inner ear problems can include problems with balance and problems with hearing. These problems may be permanent. If used during pregnancy it can cause harm to the baby. It appears to be safe for use during breastfeeding. Gentamicin is a type of aminoglycoside. It works by stopping the bacteria from making protein, which typically kills the bacteria.
Gentamicin was discovered in 1963. It is made from the bacteria Micromonospora purpurea. Gentamicin is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The injectable's wholesale cost in the developing world in 2014 was between US$0.05 and US$0.58 per ml.
Active against a wide range of bacterial infections, mostly Gram-negative bacteria including Pseudomonas, Proteus, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Serratia, and the Gram-positive Staphylococcus. Gentamicin is used in the treatment of respiratory tract infections, urinary tract infections, blood, bone and soft tissues infections of these susceptible bacteria.
Gentamicin is not used for Neisseria gonorrhoeae, Neisseria meningitidis or Legionella pneumophila bacterial infections (because of the risk of the person going into shock from lipid A endotoxin found in certain Gram-negative organisms). Gentamicin is also useful against Yersinia pestis, its relatives, and Francisella tularensis (the organism responsible for Tularemia seen often in hunters and/or trappers).
Adverse effects of gentamicin can range from less severe reactions such as nausea and vomiting to more severe reactions such as:
- Low blood counts
- Allergic responses
- Neuromuscular problems
- Nerve damage
- Kidney damage (nephrotoxicity)
- Ear disorders (ototoxicity)
Nephrotoxicity and ototoxicity are thought to be dose related with higher doses causing greater chance of toxicity. These two toxicities may have delayed presentation, sometimes not appearing until after completing treatment.
Kidney damage is a problem in 10-25% of people who receive aminoglycosides, and gentamicin is one of the most nephrotoxic of the class. Oftentimes acute nephrotoxicity is reversible, but it may be fatal. The risk of nephrotoxicity can be affected by the dose, frequency, duration of therapy, and concurrent use of certain medications such as NSAIDs, diuretics, cisplatin, ciclosporin, cephalosporin, amphotericin, iodide contrast media, and vancomycin.
Factors that increase risk of nephrotoxicity include:
- Increased age
- Reduced renal function
- Hepatic dysfunction
- Volume depletion
- Metabolic acidosis
- Sodium depletion
11% of the population who receives aminoglycosides experience damage to their inner ear. The common symptoms of inner ear damage are: tinnitus, hearing loss, vertigo, trouble with coordination, dizziness. Chronic use of gentamicin can affect two area of the ears. First, damage of the inner ear hair cells can result in irreversible hearing loss. Second, damage to inner ear vestibular apparatus can lead to balance problems. To reduce the risk of ototoxicity it is recommended to stay hydrated.
- High blood uric acid levels
- Kidney dysfunction
- Liver dysfunction
- Higher doses
- Long courses of therapy
- Also taking strong diuretics (e.g. furosemide)
Mechanism of action
Gentamicin is a bactericidal antibiotic that works by irreversibly binding the 30S subunit of the bacterial ribosome, interrupting protein synthesis. This mechanism of action is similar to other aminoglycosides.
Gentamicin is composed of a number of related gentamicin components and fractions which have varying degrees of antimicrobial potency. The main components of gentamicin include members of the gentamicin C complex: gentamicin C1, gentamicin C1a, and gentamicin C2 which compose approximately 80% of gentamicin and have been found to have the highest antibacterial activity. Gentamicin A, B, X, and a few others make up the remaining 20% of gentamicin and have lower antibiotic activity than the gentamicin C complex. The exact composition of a given sample or lot of gentamicin is not well defined, and the level of gentamicin C components or other components in gentamicin may differ from lot-to-lot depending on the gentamicin manufacturer or manufacturing process. Because of this lot-to-lot variability, it can be difficult to study various properties of gentamicin including pharmacokinetics and microorganism susceptibility if there is an unknown combination of chemically related but different compounds.
Pregnancy and breastfeeding
Gentamicin is not recommended in pregnancy unless the benefits outweigh the risks for the mother. Gentamicin can cross the placenta and several reports of irreversible bilateral congenital deafness in children have been seen. Intramuscular injection of gentamicin in mothers can cause muscle weakness in the newborn.
The safety and efficacy for gentamicin in nursing mothers has not been established. Detectable gentamicin levels are found in human breast milk and in nursing babies.
Renal function should be assessed before beginning therapy and during in elderly due to a decline in glomerular filtration rate. This population can have longer than usual gentamicin levels in the body. Use cautiously in persons with renal, auditory, vestibular, or neuromuscular dysfunction.
Gentamicin may not be appropriate to use in children, including newborns and infants. Studies have shown higher serum levels and a longer half-life in this population. Check renal function periodically during therapy. Hypocalcemia, hypokalemia, and muscle weakness have been reported after gentamicin injection.
Gentamicin is produced by the fermentation of Micromonospora purpurea. It was discovered in 1963 by Weinstein, Wagman et al. at Schering Corporation in Bloomfield, N.J. working with source material (soil samples) provided by Rico Woyciesjes. Subsequently it was purified and the structures of its three components determined by Cooper, et al., also at the Schering Corporation. It was initially used as a topical treatment for burns at the Atlanta and San Antonio burn units and was introduced into IV usage in 1971. It remains a mainstay for use in sepsis.
It is synthesized by Micromonospora, a genus of Gram-positive bacteria widely present in the environment (water and soil). To highlight their specific biological origins, gentamicin and other related antibiotics produced by this genus (verdamicin, mutamicin, sisomicin, netilmicin, and retymicin) generally have their spellings ending in ~micin and not in ~mycin.
Gentamicin is also used in molecular biology research as an antibacterial agent in tissue and cell culture, to prevent contamination of sterile cultures. Gentamicin is one of the few heat-stable antibiotics that remain active even after autoclaving, which makes it particularly useful in the preparation of some microbiological growth media.
- "Gentamicin sulfate". The American Society of Health-System Pharmacists. Retrieved Aug 15, 2015.
- Bartlett, Jimmy (2013). Clinical Ocular Pharmacology (s ed.). Elsevier. p. 214. ISBN 9781483193915.
- Moulds, Robert; Jeyasingham, Melanie (October 2010). "Gentamicin: a great way to start". Australian Prescriber (33): 134–135.
- "Gentamicin use while breastfeeding". Retrieved 15 August 2015.
- Pucci, edited by Thomas Dougherty, Michael J.; Weinstein, Marvin J. (2011). Handbook of antibiotic discovery and development (2012 ed.). New York: Springer. p. 238. ISBN 9781461413998.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
- Burchum, Jacqueline (2014). Lehne's pharmacology for nursing care. Elsevier Health Sciences. p. 1051. ISBN 9780323340267.
- "Gentamicin sulfate". International Drug Price Indicator Guide. Retrieved 15 August 2015.
- "Gentamicin" (PDF). Baxter Corporation. Retrieved 2 November 2015.
- "Product Monograph" (PDF). Sandoz Canada Inc. Retrieved 2 November 2015.
- Goljan, Edward F. (2011). Rapid Review Pathology (3rd ed.). Philadelphia, Pennsylvania: Elsevier. p. 241. ISBN 978-0-323-08438-3.
- "Gentamicin spectrum of bacterial susceptibility and Resistance" (PDF). Retrieved 15 May 2012.
- Lopez-Novoa, Jose M; Quiros, Yaremi; Vicente, Laura; Morales, Ana I; Lopez-Hernandez, Francisco J (Jan 2011). "New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view". Kidney International. 79 (1): 33–45. doi:10.1038/ki.2010.337. PMID 20861826.
- East, J E; Foweraker, J E; Murgatroyd, F D (2005-05-01). "Gentamicin induced ototoxicity during treatment of enterococcal endocarditis: resolution with substitution by netilmicin". Heart. 91 (5): e32. doi:10.1136/hrt.2003.028308. ISSN 1355-6037. PMC . PMID 15831617.
- Selimoglu, Erol (2007-01-01). "Aminoglycoside-induced ototoxicity". Current Pharmaceutical Design. 13 (1): 119–126. doi:10.2174/138161207779313731. ISSN 1873-4286. PMID 17266591.
- Weinstein, Marvin J. (1967). "Biological Activity of the Antibiotic Components of the Gentamicin Complex". Journal of Bacteriology. 94.3: 789–790.
- Vydrin, A. F. (2003). "Component Composition of Gentamicin Sulfate Preparations". Pharmaceutical Chemistry Journal. 37.8: 448–449.
- Isoherranen, Nina; Eran, Lavy (2000). "Pharmacokinetics of Gentamicin C1, C1a, and C2 in Beagles after a Single Intravenous Dose". Antimicrobial Agents and Chemotherapy. 44.6: 1443–1447. doi:10.1128/aac.44.6.1443-1447.2000.
- Weinstein, Marvin; Wagman (1963). "Gentamicin, A New Antimicrobial Complex from Micromonospora". J Med Chem. 6: 463–464. doi:10.1021/jm00340a034.